Promoter Hypermethylation-mediated Inactivation of LRRC4 in Gliomas

BMC Molecular Biology, Nov 2008

Background Leucine-rich repeat C4 protein (LRRC4) is a new member of the leucine-rich repeat (LRR) superfamily. It is not only a brain-specific gene but also a novel candidate for tumor suppression. LRRC4 inactivation is commonly found in glioma cell lines and primary glioma biopsies. However, little is known about the mechanism controlling LRRC4 expression. In a previous study, we did not find any genetic alteration in LRRC4 in primary glioma, which led us to explore an alternative mechanism underlying this phenomenon. Methods In the present paper, we cloned the LRRC4 promoter with characteristics of a CpG island by luciferase reporter assay. Then, the CpG methylation status around the LRRC4 promoter region in glioma cell lines and primary gliomas was examined by methylation-specific PCR and bisulfite DNA sequencing. In order to demonstrate a functional association between LRRC4 promoter methylation and its gene inactivation, we performed DNA demethylation analysis with two human glioma cell lines using methylation-specific PCR and RT-PCR. Results The sequence spanning positions -835 to -293 relative to the translation start site was identified as the LRRC4 promoter; this sequence is a TATA- and CAAT- less, high GC content region. It was found that LRRC4 promoter activity is strongly suppressed after treatment with SssI methylase in vitro. Furthermore, LRRC4 promoter methylation was observed by methylation-specific PCR in two glioma cell lines and all 30 primary glioma specimens, but not in normal brain tissue. Bisulfite DNA sequencing showed that most of the CpG sites were located around the LRRC4 promoter methylated in glioma cells and tissues, but not in normal brain tissue. In addition, the methylase inhibitor 5-Aza-2'-deoxycytidine could induce LRRC4 mRNA expression and LRRC4 promoter partial demethylation in SF126 and SF767 glioma cells. Conclusion Methylation-mediated inactivation of LRRC4 is a frequent and glioma-specific event, and it may be a potential biomarker for diagnosis or prognosis, or serve as a therapeutic target.

A PDF file should load here. If you do not see its contents the file may be temporarily unavailable at the journal website or you do not have a PDF plug-in installed and enabled in your browser.

Alternatively, you can download the file locally and open with any standalone PDF reader:

http://www.biomedcentral.com/content/pdf/1471-2199-9-99.pdf

Promoter Hypermethylation-mediated Inactivation of LRRC4 in Gliomas

0 The Third Affiliated Hospital of Xiang Ya School of Medicine, Central South University , Changsha 410078, Hunan , PR China 1 Department of Parasitology, Central South University , Changsha 410078, Hunan , PR China 2 Cancer Research Institute, Central South University , Changsha 410078, Hunan , PR China Background: Leucine-rich repeat C4 protein (LRRC4) is a new member of the leucine-rich repeat (LRR) superfamily. It is not only a brain-specific gene but also a novel candidate for tumor suppression. LRRC4 inactivation is commonly found in glioma cell lines and primary glioma biopsies. However, little is known about the mechanism controlling LRRC4 expression. In a previous study, we did not find any genetic alteration in LRRC4 in primary glioma, which led us to explore an alternative mechanism underlying this phenomenon. Methods: In the present paper, we cloned the LRRC4 promoter with characteristics of a CpG island by luciferase reporter assay. Then, the CpG methylation status around the LRRC4 promoter region in glioma cell lines and primary gliomas was examined by methylation-specific PCR and bisulfite DNA sequencing. In order to demonstrate a functional association between LRRC4 promoter methylation and its gene inactivation, we performed DNA demethylation analysis with two human glioma cell lines using methylation-specific PCR and RT-PCR. Results: The sequence spanning positions -835 to -293 relative to the translation start site was identified as the LRRC4 promoter; this sequence is a TATA- and CAAT- less, high GC content region. It was found that LRRC4 promoter activity is strongly suppressed after treatment with SssI methylase in vitro. Furthermore, LRRC4 promoter methylation was observed by methylationspecific PCR in two glioma cell lines and all 30 primary glioma specimens, but not in normal brain tissue. Bisulfite DNA sequencing showed that most of the CpG sites were located around the LRRC4 promoter methylated in glioma cells and tissues, but not in normal brain tissue. In addition, the methylase inhibitor 5-Aza-2'-deoxycytidine could induce LRRC4 mRNA expression and LRRC4 promoter partial demethylation in SF126 and SF767 glioma cells. Conclusion: Methylation-mediated inactivation of LRRC4 is a frequent and glioma-specific event, and it may be a potential biomarker for diagnosis or prognosis, or serve as a therapeutic target. - Background Gliomas are the most common malignant tumors in the adult central nervous system and account for 50 to 60% of primary brain tumors. These cancers exhibit a relentless malignant progression characterized by widespread invasion throughout the brain, and thus usually result in a poor prognosis [1]. Although multiple genetic alterations are involved in the development and progression of malignant gliomas [2,3], epigenetic silencing of wild-type tumor suppressor genes via aberrant promoter hypermethylation has also been shown to occur [4-6]. Aberrant promoter methylation of CpG island-associated genes is a common epigenetic alteration associated with the inactivation of tumor suppressor and other genes in human cancers [7-9]. Unmethylated in normal tissues, promoters of these genes can become methylated de novo in cancer cells. This change is accompanied by alterations in histone modification and chromatin conformation, rendering the promoter transcriptionally inert [10]. Such epigenetic mechanisms have been implicated in the inactivation of several key regulators of the cell cycle (RB, p16INK4A, p73), DNA repair (O6MGMT), apoptosis (DAP kinase), angiogenesis (THBS1), and invasion (TIMP3) in glioma [11]. Recently, novel hypermethylated genes in glioma have been identified using a candidate gene approach or by a genome-wide screening method. The former revealed that genes such as EMP3, TMS1/ASC, SLC5A8, hMLH and PTEN are frequently targeted for DNA methylation-mediated silencing in glioma [4,5,12,13]. A genome-wide screen using a combined approach of pharmacologic inhibition of epigenetic modifications and gene expression microarrays also revealed that several novel genes are subject to aberrant hypermethylation in glioma [14,15]. Thus, aberrant methylation events have become critical to our understanding of the initiation and progression of human brain malignancies and may serve as a biomarker for diagnosis, prognosis and susceptibility to treatment. Leucine-rich repeat C4 protein (LRRC4) is a new member of the leucine-rich repeat (LRR) superfamily located at 7q31-32 [16]. It was found to be predominantly expressed in normal brain tissue and involved in early nervous system development and differentiation [17], but the expression of LRRC4 was absent in several malignant glioma cell lines [18]. Similarly, it was absent or significantly downregulated in 87.5% of primary glioma biopsies [16]. More importantly, LRRC4 had the potential to suppress tumorigenesis of U251 malignant glioma cells in vivo and cell proliferation in vitro [19]. Recent studies show that LRRC4 (...truncated)


This is a preview of a remote PDF: http://www.biomedcentral.com/content/pdf/1471-2199-9-99.pdf

Zuping Zhang, Dan Li, Minghua Wu, Bo Xiang, Li Wang, Ming Zhou, Pan Chen, Xiaoling Li, Shourong Shen, Guiyuan Li. Promoter Hypermethylation-mediated Inactivation of LRRC4 in Gliomas, BMC Molecular Biology, 2008, pp. 99, 9, DOI: 10.1186/1471-2199-9-99